Human services: medical services; exemption of certain prescription drugs from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h).
Summary
SB 397 amends Michigan’s Social Welfare Act to limit when the Department of Health and Human Services may require prior authorization for prescription drugs under Medicaid. If the department uses a prior authorization system for pharmaceutical services, the bill exempts a broad set of medications from that process, including certain central nervous system drugs such as anticonvulsants, antidepressants, antipsychotics, and noncontrolled antianxiety drugs, as well as cross-indicated drugs related to those therapies.
The bill also exempts drugs used to treat or prevent HIV/AIDS, and drugs used for cancer, organ replacement therapy, epilepsy or seizure disorders, and opioid withdrawal symptom management or opioid use disorder. For opioid use disorder and opioid withdrawal treatment, the bill specifically bars the department from imposing a dosage maximum. It also clarifies that these protections apply both in fee-for-service Medicaid and in contracts with health maintenance organizations or managed care organizations, so long as those contracts comply with the new requirements.
Impact
The bill would amend MCL 400.109h to narrow the state’s ability to use prior authorization as a utilization-management tool for specified Medicaid prescription drugs. In practice, it would reduce administrative barriers for beneficiaries and prescribers seeking access to the listed medications, while limiting the department’s discretion to deny or delay coverage for those drug classes and indications. It also reinforces that managed care arrangements must follow the same exemption rules, affecting both state-administered and contracted pharmaceutical services under the medical assistance program.
Sentiment
The available voting record shows strong support for the bill. It was reported favorably out of committee on a 10-0 vote and then passed the Senate unanimously 36-0. No committee transcript was provided, but the unanimous votes suggest broad agreement that the bill improves access to important medications and reduces prior authorization burdens for Medicaid patients and providers.
Contention
No major opposition is reflected in the provided materials. The main policy issue implicit in the bill is the tradeoff between easier access to medications and the department’s ability to manage costs, utilization, and clinical oversight through prior authorization. The bill’s most specific constraint is on opioid-related treatment, where it prohibits dosage caps for opioid withdrawal symptom management or opioid use disorder, indicating a focus on access that may be the most notable point of policy sensitivity even though no recorded dissent appears in the vote history.